The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy
Andy Hsu, H. Miles Prince(Monash University), Joseph A. Trapani(University of Melbourne), Paul J. Neeson(The University of Melbourne), Tsin Yee Tai(Cornell University), Hang Quach(The University of Melbourne), Simon J. Harrison(The University of Melbourne), Mark J. Smyth(The University of Queensland)
Cited by 156
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657